Immix Biopharma (IMMX) announced that new NXC-201 NEXICART-1 clinical data in relapsed/refractory AL Amyloidosis has been presented at 66th American Society of Hematology Annual Meeting being held in San Diego, California. The updated results include follow-up and clinical data from 3 new NEXICART-1 patients. “We are encouraged by the updated NXC-201 results being presented by our academic collaborators at ASH 2024. We believe the high percentage of complete responders, combined with the consistent, attractive tolerability profile is critically important in relapsed/refractory AL Amyloidosis. This expanded NXC-201 dataset continues to bolster our leadership in relapsed/refractory AL Amyloidosis, where no drugs are FDA approved today,” said Ilya Rachman, M.D., Ph.D., CEO of Immix Biopharma. At the NXC-201 ASH 2024 oral presentation, data were presented from 16 relapsed/refractory AL amyloidosis patients (including 3 new patients) in the ongoing Phase 1b/2 NEXICART-1 study, with median 4 lines of therapy prior to NXC-201. Patients were infused with CAR+T cells at doses of 150 x 106 (n=1), 450 x 106 (n=2), and 800 x 106 (n=13). Safety and efficacy data: Overall response rate of 94% (15/16); Complete response rate of 75% (12/16) (9 out of 16 were MRD- 10-5); Organ response rate of 62% (8/13 evaluable); Best responder had a duration of response of 31.5 months as of December 9, 2024, with complete response ongoing; There were no immune effector cell-associated neurotoxicity syndrome events.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio